ATE556053T1 - Piperidinderivate zur behandlung von alzheimer- krankheit - Google Patents

Piperidinderivate zur behandlung von alzheimer- krankheit

Info

Publication number
ATE556053T1
ATE556053T1 AT07733599T AT07733599T ATE556053T1 AT E556053 T1 ATE556053 T1 AT E556053T1 AT 07733599 T AT07733599 T AT 07733599T AT 07733599 T AT07733599 T AT 07733599T AT E556053 T1 ATE556053 T1 AT E556053T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
treatment
piperidine derivatives
modulate
Prior art date
Application number
AT07733599T
Other languages
English (en)
Inventor
Andrew Madin
Mark Peter Ridgill
Janusz Josef Kulagowski
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE556053T1 publication Critical patent/ATE556053T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT07733599T 2006-04-07 2007-04-02 Piperidinderivate zur behandlung von alzheimer- krankheit ATE556053T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0606985.0A GB0606985D0 (en) 2006-04-07 2006-04-07 Therapeutic agents
PCT/GB2007/050176 WO2007116228A1 (en) 2006-04-07 2007-04-02 Piperidine derivatives for treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE556053T1 true ATE556053T1 (de) 2012-05-15

Family

ID=36539492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07733599T ATE556053T1 (de) 2006-04-07 2007-04-02 Piperidinderivate zur behandlung von alzheimer- krankheit

Country Status (5)

Country Link
US (1) US7985758B2 (de)
EP (1) EP2007724B1 (de)
AT (1) ATE556053T1 (de)
GB (1) GB0606985D0 (de)
WO (1) WO2007116228A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420622B2 (en) 2006-12-20 2013-04-16 Merck, Sharp & Dohme, Corp. Silylated piperidine derivatives
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2010071741A1 (en) 2008-12-16 2010-06-24 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of alzheimer's disease
WO2015109109A1 (en) 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
WO2016201168A1 (en) 2015-06-10 2016-12-15 Forum Pharmceuticals Inc. Oxadiazine compounds and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600952B1 (de) * 1991-08-20 1996-04-17 MERCK SHARP & DOHME LTD. Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ES2124318T3 (es) * 1992-07-28 1999-02-01 Merck Sharp & Dohme Compuestos azaciclicos.
GB0423356D0 (en) * 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
US7985758B2 (en) 2011-07-26
WO2007116228A1 (en) 2007-10-18
US20090186919A1 (en) 2009-07-23
EP2007724B1 (de) 2012-05-02
GB0606985D0 (en) 2006-05-17
EP2007724A1 (de) 2008-12-31

Similar Documents

Publication Publication Date Title
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE368031T1 (de) Neue gamma secretase inhibitoren
ATE386028T1 (de) Zyklohexylsulfone als gamma-sekretase-inhibitoren
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE444293T1 (de) Cyclische sulfamide zur inhibierung von gamma- sekretase
MX2010002674A (es) Moduladores de gamma secretasa.
ATE534377T1 (de) Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
MX2010006378A (es) Moduladores de gamma secretasa.
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MX2010006379A (es) Moduladores de la secretasa gamma.
MX2010005028A (es) Moduladores de gamma secretasa.
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ATE461923T1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ATE530525T1 (de) Piperidine und verwandte verbindungen zur behandlung von demenz
NO20076405L (no) Anvendelse av 24-nor-UDCA
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
DE602006020775D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
MX2009012525A (es) Pirazol-pirrolidinas como inhibidores de gamma secretasa.
ATE556053T1 (de) Piperidinderivate zur behandlung von alzheimer- krankheit
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
BRPI0817433A2 (pt) Moduladores de gama-secretase piperidinila e piperazinila